With regard to treatment modalities, more than 50 % of the pharmacists were knowledgeable of using adjuvant endocrine therapy for patients with estrogen receptor positive invasive breast cancer, using tamoxifen as the adjuvant endocrine therapy of choice for premenopausal patients with invasive breast cancer, and the length of treatment. The gene discussed is ESR1; the disease is invasive breast carcinoma.